AAKAAR2025-10-012026-03-31AAKAAR2026-03-31AAKAAR2025-03-31AAKAAR2025-04-012026-03-31AAKAAR2025-10-012026-03-31in-capmkt:OtherExpenses1MemberAAKAAR2025-04-012026-03-31in-capmkt:OtherExpenses1MemberAAKAAR2026-03-31OtherLongTermLiabilitiesDomain1AAKAAR2026-03-31OtherCurrentLiabilitiesDomain1AAKAAR2026-03-31OtherNoncurrentAssetsDomain1AAKAAR2026-03-31OtherCurrentAssetsDomain1AAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2025-04-012026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2025-04-012026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2025-04-012026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2025-04-012026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2026-03-31in-capmkt:ReportableSegments1MemberAAKAAR2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2026-03-31in-capmkt:ReportableSegments2MemberAAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain1AAKAAR2025-09-30RelatedPartyTransactionDomain1AAKAAR2026-03-31RelatedPartyTransactionDomain1AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain2AAKAAR2025-09-30RelatedPartyTransactionDomain2AAKAAR2026-03-31RelatedPartyTransactionDomain2AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain3AAKAAR2025-09-30RelatedPartyTransactionDomain3AAKAAR2026-03-31RelatedPartyTransactionDomain3AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain4AAKAAR2025-09-30RelatedPartyTransactionDomain4AAKAAR2026-03-31RelatedPartyTransactionDomain4AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain5AAKAAR2025-09-30RelatedPartyTransactionDomain5AAKAAR2026-03-31RelatedPartyTransactionDomain5AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain6AAKAAR2025-09-30RelatedPartyTransactionDomain6AAKAAR2026-03-31RelatedPartyTransactionDomain6AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain7AAKAAR2025-09-30RelatedPartyTransactionDomain7AAKAAR2026-03-31RelatedPartyTransactionDomain7AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain8AAKAAR2025-09-30RelatedPartyTransactionDomain8AAKAAR2026-03-31RelatedPartyTransactionDomain8AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain9AAKAAR2025-09-30RelatedPartyTransactionDomain9AAKAAR2026-03-31RelatedPartyTransactionDomain9AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain10AAKAAR2025-09-30RelatedPartyTransactionDomain10AAKAAR2026-03-31RelatedPartyTransactionDomain10AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain11AAKAAR2025-09-30RelatedPartyTransactionDomain11AAKAAR2026-03-31RelatedPartyTransactionDomain11AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain12AAKAAR2025-09-30RelatedPartyTransactionDomain12AAKAAR2026-03-31RelatedPartyTransactionDomain12AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain13AAKAAR2025-09-30RelatedPartyTransactionDomain13AAKAAR2026-03-31RelatedPartyTransactionDomain13AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain14AAKAAR2025-09-30RelatedPartyTransactionDomain14AAKAAR2026-03-31RelatedPartyTransactionDomain14AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain15AAKAAR2025-09-30RelatedPartyTransactionDomain15AAKAAR2026-03-31RelatedPartyTransactionDomain15AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain16AAKAAR2025-09-30RelatedPartyTransactionDomain16AAKAAR2026-03-31RelatedPartyTransactionDomain16AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain17AAKAAR2025-09-30RelatedPartyTransactionDomain17AAKAAR2026-03-31RelatedPartyTransactionDomain17AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain18AAKAAR2025-09-30RelatedPartyTransactionDomain18AAKAAR2026-03-31RelatedPartyTransactionDomain18AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain19AAKAAR2025-09-30RelatedPartyTransactionDomain19AAKAAR2026-03-31RelatedPartyTransactionDomain19AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain20AAKAAR2025-09-30RelatedPartyTransactionDomain20AAKAAR2026-03-31RelatedPartyTransactionDomain20AAKAAR2025-10-012026-03-31RelatedPartyTransactionDomain21AAKAAR2025-09-30RelatedPartyTransactionDomain21AAKAAR2026-03-31RelatedPartyTransactionDomain21AAKAAR2025-10-012026-03-31AuditorDomain1AAKAAR2026-03-31Statement1AAKAAR2025-10-012026-03-31Statement1AAKAAR2026-03-31StatementDynamic1I1Statement1AAKAAR2026-03-31StatementDynamic1I2Statement1AAKAAR2026-03-31StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000AAKAARNOTLISTEDINE1GYP01013AAKAAR MEDICAL TECHNOLOGIES LIMITEDSMEEquity2025-04-012026-03-312026-05-152026-04-01INRLakhsHalf YearlyYearlyMulti segment2026-05-1515:35:002026-05-1516:00:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2024-12-19www.aakaarmedical.intrue1falseNot applicable2025-10-012026-03-31AuditedStandalone416392000634800042274000023817000150179000-6390000674680007554000792000771690003205890001021510000102151000010215100028134000-19900027935000742160000007421600074216000141728000105.245.240.00340.11390.16511. The Financial Results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognized accounting practices and policies as applicable. <BR> <BR> 2. The above results were reviewed by Audit Committee and were approved and taken on record by the Board of Directors in their meeting held on 15th May, 2026. <BR> <BR> 3. Basic and Diluted EPS have been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20. <BR> <BR> 4. The Company operates through two segments viz. manufacturing and distribution of Aesthetic Devices & Device consumables and Aesthetic Products. Details of the same are as per the annexure attached. <BR> <BR> 5. The figures for the half year ended March 2026 & March 2025 are the balancing figures between the audited figures of full financial year and the figures upto half year ended September 2025 and September 2024 respectively. <BR> <BR> 6. The Company has issued and allotted 37,50,400 Equity Shares of face value of Rs 10 each at the price of Rs 72 each (including Rs 62 Security Premium) for total consideration of Rs. 2,700.29 Lakhs through SME IPO (Initial Public Offer) on National Stock Exchange of India (NSE). Pursuant to the allotment of Equity shares, the paid-up Equity Share capital of the company stands increased at Rs. 1417.28 Lakhs. <BR> <BR> 7. The details of utilization of IPO Proceeds of Rs. 2700.29 lakhs are as follows: <BR> (Rs. in lacs) <BR> Particulars Proceeds Utilisation upto March, 2026 Unutilised upto 31st March, 2026* <BR> <BR> Working Capital 2,035.00 935.00 1,100.00 <BR> General Corporate <BR> Purpose** 329.00 0.63 328.37 <BR> Issue expenses <BR> paid with GST 336.29 336.29 - <BR> <BR> Total 2,700.29 1,271.92 1,428.37 <BR> <BR> (*The above unutilised amount as at 31st March 2026, has been kept in a fixed deposit with a scheduled bank.) <BR> (**The GCP Component 0.63 includes issues expenses 0.63 Lacs with GST on and above estimated issue expenses of Rs. 336.29 lacs paid - with GST.) <BR> <BR> 8. Previous year figures have been regrouped / rearranged wherever necessary to correspond with the current <BR> year's classification / disclosures.2025-04-012026-03-31AuditedStandalone669641000804400067768500044098000289913000-519610001401080001796100012830001443650005857670009191800009191800009191800026280000-73800025542000663760000006637600066376000141728000104037780004.994.990.00340.04090.0656Other Expenses77169000Other Expenses1443650001417280004037780000545506000000009829000098290001853430007006000118400001884600020432000142100002388310007941660001694000012060000039740006874000046970000312100013353000280450000197504000372252000161690000743000334000335980007661210007941660001. The Financial Results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognized accounting practices and policies as applicable. <BR> <BR> 2. The above results were reviewed by Audit Committee and were approved and taken on record by the Board of Directors in their meeting held on 15th May, 2026. <BR> <BR> 3. Basic and Diluted EPS have been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20. <BR> <BR> 4. The Company operates through two segments viz. manufacturing and distribution of Aesthetic Devices & Device consumables and Aesthetic Products. Details of the same are as per the annexure attached. <BR> <BR> 5. The figures for the half year ended March 2026 & March 2025 are the balancing figures between the audited figures of full financial year and the figures upto half year ended September 2025 and September 2024 respectively. <BR> <BR> 6. The Company has issued and allotted 37,50,400 Equity Shares of face value of Rs 10 each at the price of Rs 72 each (including Rs 62 Security Premium) for total consideration of Rs. 2,700.29 Lakhs through SME IPO (Initial Public Offer) on National Stock Exchange of India (NSE). Pursuant to the allotment of Equity shares, the paid-up Equity Share capital of the company stands increased at Rs. 1417.28 Lakhs. <BR> <BR> 7. The details of utilization of IPO Proceeds of Rs. 2700.29 lakhs are as follows: <BR> (Rs. in lacs) <BR> Particulars Proceeds Utilisation upto March, 2026 Unutilised upto 31st March, 2026* <BR> <BR> Working Capital 2,035.00 935.00 1,100.00 <BR> General Corporate <BR> Purpose** 329.00 0.63 328.37 <BR> Issue expenses <BR> paid with GST 336.29 336.29 - <BR> <BR> Total 2,700.29 1,271.92 1,428.37 <BR> <BR> (*The above unutilised amount as at 31st March 2026, has been kept in a fixed deposit with a scheduled bank.) <BR> (**The GCP Component 0.63 includes issues expenses 0.63 Lacs with GST on and above estimated issue expenses of Rs. 336.29 lacs paid - with GST.) <BR> <BR> 8. Previous year figures have been regrouped / rearranged wherever necessary to correspond with the current <BR> year's classification / disclosures.Provision for Gratuity9829000Other Current Liabilities20432000Other Non Current Assets13353000Other Current Assets33598000Aesthetic Devices & Device Consumables40066000Aesthetic Products376326000Aesthetic Devices & Device Consumables73566000Aesthetic Products596075000416392000669641000416392000669641000Aesthetic Devices & Device Consumables13234000Aesthetic Products235553000Aesthetic Devices & Device Consumables29984000Aesthetic Products35760600024878700038759000075540001796100013908200027771100010215100091918000Aesthetic Devices & Device Consumables103523000Aesthetic Products466233000569756000224411000794167000Aesthetic Devices & Device Consumables0Aesthetic Products002486600002486600001654500012830000-15100000030420000020719000-51961000-952500002046000-16118000-79780003309000-165952000-145233000-5331500000-7797000225010000-8361300000-83613000000000000578200000000005776000049300004870000048700027002900000025460000000-5660500018796400000187964000104838000010483800055465000160303000Aakaar Medical Technologies Limited******Dilip Ramesh Meswani******Founder, Managing Director and PromoterRemuneration2700000NA27000002025-06-14135000000Aakaar Medical Technologies Limited******Dilip Ramesh Meswani******Founder, Managing Director and PromoterLoan25000000NA250000002025-02-25895000089500000Loan0.095 yearsUnsecuredWorking CapitalCurrent year loan repayment done for 89.5 LakhsAakaar Medical Technologies Limited******Dilip Ramesh Meswani******Founder, Managing Director and PromoterAny other transactionInterest on loan16425000NA164250002025-02-2535000000Aakaar Medical Technologies Limited******Bindi Dilip Meswani******Chairperson and PromoterAny other transactionConsultation Fees1500000NA15000002025-08-1375000000Aakaar Medical Technologies Limited******Bindi Dilip Meswani******Chairperson and PromoterAny other transactionRent200000NA2000002025-02-25126000000Aakaar Medical Technologies Limited******Milouni Dilip Meswani******Manager and Promoter Grp Member and daughter of MDRemuneration1320000NA13200002025-08-1366000000Aakaar Medical Technologies Limited******Rita Meswani******Sister of MD and Promoter Grp MemberRemuneration360000NA3600002025-08-1318000000Aakaar Medical Technologies Limited******Abhash Dilip Meswani******Son of Founder & MD and Promoter Grp MemberAny other transactionRent1255000NA12550002025-02-2565500000Aakaar Medical Technologies Limited******Dr. Rahul Sawakhande******C.E.O. & DirectorRemuneration9996000NA99960002025-06-14499800000Aakaar Medical Technologies Limited******Dr. Rahul Sawakhande******C.E.O. & DirectorAny other transactionLoan given to CEO4195000NA41950002025-02-2513900035950003455000Loan012 yearsUnsecuredPurchase of ESOP grantedLoan given by Company to CEO FY 24-25Aakaar Medical Technologies Limited******Rajendra Dhandhukia******Independent DirectorRemuneration100000NA1000002025-02-255000000Aakaar Medical Technologies Limited******Deepanjan Periwal******Independent DirectorRemuneration100000NA1000002025-02-255000000Aakaar Medical Technologies Limited******Anoopkumar Pillai******Company Secretary & Compliance OfficerRemuneration1200000NA12000002025-02-2560000000Aakaar Medical Technologies Limited******Rakesh Parekh******Chief Financial OfficerRemuneration1800000NA18000002025-12-1551700000Aakaar Medical Technologies Limited******Aesthetic Solutions -HUF******Founder and MD is the Karta of HUFSale of goods or services1000000NA10000002025-02-2519700000Aakaar Medical Technologies Limited******Rajendra Dhandhukia******Independent DirectorAny other transactionProfessional Fees25000NA250002025-02-252500000Aakaar Medical Technologies Limited******Deepanjan Periwal******Independent DirectorAny other transactionProfessional Fees50000NA500002025-02-255000000Aakaar Medical Technologies Limited******Bindi Dilip Meswani******Chairperson and PromoterAny other transactionInterest on loan369000NA3690002025-02-25500000Aakaar Medical Technologies Limited******Shweta Shah******Chief Financial OfficerRemuneration1348000NA13480002025-02-2529600000Aakaar Medical Technologies Limited******Sharda Meswani******Mother of Founder & MD and Promoter Grp MemberAny other transactionInterest on loan280000NA2800002025-02-251400000Aakaar Medical Technologies Limited******Shruti Mishra******Consultant and Relative of MD and ChairmanAny other transactionConsultation Fees1500000NA15000002026-02-122010000021297000AuditedtrueC.B.Mehta & Associatestrue2027-07-31Public Issues2025-06-272700290002026-03-31falsefalseNANo CommentsNo CommentsRakesh ParekhChief Financial OfficerMUMBAI2026-05-15Working Capital RequirementNo2035000000935000000General Corporate PurposeNo329000000630000Issue Expenses with GSTNo336290000336290000